Dioxins and polychlorinated biphenyls (PCBs) in fish oil
Omega-3 fatty acids.
Over the last two decades, the popularity of these products has increased concurrently with scientific research that has investigated the benefits of these oils in addressing a number of human maladies, including cardiovascular disease, stroke, high blood pressure, renal injury, rheumatoid arthritis and autoimmune disorders (Tran 2001 , Mori et al. 1994 , Donadio et al 1994 , Schmitz et al 2002 , Mason P 2000 . At least some of the benefits of fish oils are thought to be due to the long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), eicosapentaenoic acid (EPA) and F o r P e e r R e v i e w O n l y docosahexaenoic acid (DHA), the presence and levels of which are increasingly being included on the labels of fish oil products. The latter compound is essential for the development of the central nervous system, whilst the former is used by the body to produce prostaglandins and is also incorporated into cell lipids, including those in the cell membrane. In recent years, these products have been specifically targeted towards children suffering from dyslexia, dyspraxia, attention-deficit hyperactivity disorder (ADHD) and other similar disorders.
One of the main non-clinical disadvantages of using fish oils as dietary supplements, which has emerged in recent years, is the presence of environmental contaminants in these products. The natural habitat of these fish species -the continental shelf specially around the North Sea and the Atlantic Ocean, has experienced the build-up of persistent organic contaminants such as PCBs, dioxins, polybrominated diphenylethers (PBDEs), polycyclic aromatic hydrocarbons (PAHs) and various pesticides through atmospheric deposition, run-off and pollution from shipping. This has resulted in an enrichment of these pollutants, particularly in coastal sediments and, consequently, in the marine food chain. Many fish species bio-accumulate these contaminants, which are lipophilic and thus associate with lipid-rich tissues such as the liver and oil-rich muscle. As noted earlier, fish oil dietary supplements are produced from such tissues and the initial crude product can contain very high levels of these contaminants. The actual concentrations observed are dependent not only on the species but also on the geographical location (Brevik et al. 1990) , with products sourced from the Southern Hemisphere generally showing lower levels of environmental contamination than those from Northern Hemisphere locations such as parts of the North Sea and especially the Baltic Sea, which is very contaminated with dioxins. The age of the fish and type of tissue used may also influence the contaminant levels, with data suggesting that oil derived from the liver is often more contaminated than muscle tissue oil.
In an effort to remove these contaminants, the industry employs a number of refining processes. General refining may include processes such as odour removal by steam stripping, exclusion of high molecular weight compounds by cold filtration and removal of other undesirable contaminants by activated charcoal filtration, as well as other chemical methods (Brevik et al. 1990 ). However, molecular distillation (using a temperature range of 180 -220 0 C at < 100Pa) is far more effective at removing halogenated contaminants, especially PCBs. A drawback of some of the refining processes is that beneficial components of the fish oils, such as EPA and DHA, are removed at the same time as the contaminants, and the refining process employed must therefore strike a balance between contaminant removal and omega-3 fatty acid retention. Thus, some manufacturers have invested in developing newer (undisclosed) purification methods that are able to achieve this balance and are claiming success.
An alternative means of reducing the dietary exposure to consumers but without further purification is, of course, to reduce the manufacturer recommended dosage, especially for children.
The last survey of fish oil dietary supplements for PCBs and dioxins, carried out by the Ministry of Agriculture, Fisheries and Food in the UK in the mid-1990s, studied levels of these contaminants in retail products purchased in 1994 and 1996.
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Sampling and Analysis
A total of 33 dietary supplement products, comprising mostly cod liver oils but also salmon oils, other fish oils and formulations of cod liver oil with orange syrup or lemon flavouring, were purchased from retail outlets and by mail order during 2001-02. It was assumed that sampling would be representative, as these products are distributed nationally across the UK. Products that were sampled in previous surveys in the UK (MAFF 1997) were included where they were still available for purchase, along with a number of additional products. On receipt at the laboratory, each sample was given a unique laboratory reference number and the sample details logged into a database.
Product expiry dates were checked to ensure validity of the shelf-life of the samples during the measurement period. Information on recommended dosage provided on Nos. 18, 28, 31, 47, 49, 51, 52, 99, 101, 105, 114, 118, 123, 128, 138, 153, 156, 157, 167, 180, 189 
Results and Discussion
All of the samples that formed part of this study showed detectable levels of PCDD/Fs and PCBs apart from one cod liver oil sample in which the PCDD/Fs were below detection limits. The reporting limit quoted for non-ortho-PCBs and dioxin congeners was the limit of determination that prevailed in that instance. The limit varied for different congeners but, at its lowest value, was 0.02 ng/kg fat. For the ortho-PCBs, a reporting limit of 0.10 µg/kg fat was applied.
Insert Table 1 here Summary data for all individual samples, presented as Σ WHO-TEQ for each class of PCDD/Fs, non-ortho-PCBs, and ortho-PCBs, as well as total Σ PCDD/F+PCB WHO-TEQ, is presented in Table 1 . Details of the origin and brand of the products is given elsewhere (FSA 2002) . The Σ ICES 7 PCBs is also included. The WHO-TEQ data were calculated using the appropriate WHO-TEF values (Van den Berg et al. 1998) and summed to give Σ WHO-TEQ (all WHO-TEQ data quoted in this work has been calculated in this way). Data are reported as upper-bound, which means that, in cases where congeners were not detected, they were assumed to be present at a concentration equivalent to the detection limit. As most of the samples in this survey were oils, whole weight basis TEQs would be equivalent to the fat weight basis data and have therefore not been reported separately. One sample that was a mixture (of unspecified proportions) of cod liver oil and orange syrup has been excluded from the statistical analysis which is shown in Table 2 .
Insert Table 2 here
These data show that the major contribution to the total Σ WHO-TEQ comprises the PCBs, with approximately 55% from the non-ortho-PCBs and 24% from the ortho- PCBs, the remainder coming from the PCDD/F contribution. This is in agreement with observations on fish oil and fish in general, as reported by other workers (Fernandes et al 2004b , Falandysz et al 1994 , Jiminez et al 1996 , Jacobs et al 2002 CFIA 2004 , Bordajandi et al 2000 , MAFF 1999 . In particular, when compared to another contemporaneous survey of fish oils commissioned by the Food Safety Authority of Ireland (FSAI, 2002) , the contribution from PCDD/Fs to the ΣWHO-TEQ is the same, at 21% (Table 3 ). The data are not directly comparable with the UK data. The apparent differences between the countries are largely due to the range and relative quantities of products and brands surveyed. In the UK survey, twelve of the 32 samples are derived from a single manufacturer's product. These samples showed consistently lower TEQ levels than the majority of other fish oil supplements. The
Irish survey, on the other hand, only contains one sample of this product.
Consequently, the UK data show a much higher proportion of lower concentrations compared to the Irish data. Therefore, the UK data has a lower mean and median, and is more skewed. The Irish data shows a much more even distribution with good agreement between the mean and median values and a very low skewness.
Nevertheless, the results for the two countries are broadly similar. Both sets of data are positively skewed, and the observed TEQ levels are of the same order of magnitude. The distributions for both sets of PCB WHO-TEQ data are shown in Figure 1 , which gives histograms for both sets of data.
Insert Table 3 here
Insert Figure 1 here
The congener profiles for samples in this study are generally similar with the 2, 3, 7, 2, 3, 4, 7, 2, 3, 7, 3, 7, 8 -TCDF also make significant, though smaller contributions. It must be emphasised that these observations refer to the fish oil data in the group of samples discussed in this paper and may reflect the effects of the purification procedures used by manufacturers, rather than the original contaminant levels in the oil. An important implication that follows is that the reduction in levels observed in this data set compared to previous data may be the result of better purification procedures or more selective sourcing of products based on geography, rather than actual reductions in the levels of contamination in the crude oil products. This view needs to be balanced with the observations on gradually declining dioxin and PCB levels in fish in general (Fernandes et al 2004b) .
Maximum limits
In The EU therefore adopted a strategy to reduce the presence of dioxins and dioxin-like PCBs in food. The strategy focussed on two aspects -current and future measures to It is evident from the data for PCDD/Fs presented in Table 1 , that 12 products contained PCDD/Fs at concentrations in excess of what was to become the limit. Of these, 11 were cod liver oils and one was a salmon oil. A further cod liver oil product exceeded the future action limit. On the other hand, approximately 64% of the products surveyed contained PCDD/F concentrations below the limit. In view of the intention to bring dioxin-like PCBs into the Regulation, assessment is included of the dioxin-like PCB concentrations of the products surveyed. At the time of writing, the current proposal is for a total WHO-TEQ limit (dioxins plus dioxin-like PCBs) of 10 ng/kg WHO-TEQ in marine oils intended for human consumption, based on a contribution of up to 8 from dioxin-like PCBs. On this basis, 13 of the products tested would be in exceedence.
Deleted: The strategy focussed on two aspects -current and future measures to the processing of fish oils, since carbon is known to remove dioxins and furans more effectively than it does PCBs. In any event, to achieve lower PCB levels in fish oil in the future, it is highly probable that producers will need to make further technological changes. 2002) for a wide section of the population ranging from schoolchildren to adults and the elderly, based on the data obtained from this survey, and these are summarized in Table 4 . The summary distinguishes exposure from cod liver oil products and from other fish oil products, such as salmon oil. These two headings cover bottled product as well as capsules. The exposures were estimated by taking into account the suggested dosages for each of the age groups for which the products were recommended. The summary also provides estimate ranges for consumption of the products alone as well as in combination with the whole of the diet. Estimates for the dietary contribution were made from figures for mean dietary exposure as well as high level dietary exposure and were based on the 1997 Total Diet Study (FSA 2000) , the most recent data available at the time.
Insert Table 4 here
Deleted: Thus where to some extent contaminant exclusion methodologies have had some success in reducing the dioxin component of the WHO-TEQ, the emphasis should now move to excluding PCBs as well, from these products. As crude fish oils are not used it is difficult to identify a trend in these data that might reflect a decline in environmental or marine levels of these contaminants. The ranges summarized in Table 4 show that exposure resulting from cod liver oil products was generally higher than that from other fish oil products, although it is important to bear in mind that there were only 6 products in the latter group. The data also show that the consumption of some products at the manufacturer recommended doses would result in exposures exceeding the UK TDI and would provide a higher intake of dioxins than from the whole diet ( Deleted: the number of other fish oil products that were estimated for exposure were 6 as compared to 18 cod liver oil products Deleted: contents of dioxin and PCBs in these products. As observed earlier, the gradually declining dioxin and PCB levels in fish or better purification techniques, (or a combination of the two) may account for these reported exposure values.
Conclusions
This survey of fish oil dietary supplements for dioxins/furans and dioxin-like PCBs demonstrates continued surveillance in the UK of a product that can make a significant contribution to the total human exposure to these contaminants. The data obtained for dioxins and dioxin-like PCBs are in good agreement with a contemporaneous survey of fish oils carried out by the Food Safety Authority of
The results of this survey suggest that, while some products contain lower PCDD/F levels compared with earlier surveys, dioxin and dioxin-like PCB concentrations for a number of products in this survey would exceed a proposed EU limit of 10 ng/kg total WHO-TEQ, whilst the majority of products exceed an existing Norwegian limit of 3 ng/kg WHO-TEQ for dioxin-like PCBs. Since a future review is likely to drive limits down towards the values applied by Norway, fish oil purification processes will probably need to be modified to achieve a significant reduction of PCB levels.
Estimates of human exposure to different population groups resulting from consumption of the fish oil products alone, as well as in combination with an average diet, show that some products would give exposures in excess of the TDI.
Consequently, the UK FSA recommended that the relevant manufacturers withdraw affected batches of the products from sale. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The toxicological significance of the exposure data for these products needs to be balanced with the many beneficial effects that they are reported to have on human health. It is desirable to continue to benefit from these products, whilst reducing exposure to contaminants. It is therefore recommended that surveillance of these products for PCBs and dioxins should continue. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
